US equities
|
NVDA
$236.88
▲+1.25%
SPCX
$166.73
▲+4.89%
MU
$1,064.00
▼-1.01%
TSLA
$375.68
▲+1.37%
MSFT
$526.10
▲+1.66%
INTC
$116.93
▼-2.01%
SNDK
$1,718.50
▼-0.09%
META
$742.58
▲+1.99%
NVDA
$236.88
▲+1.25%
SPCX
$166.73
▲+4.89%
MU
$1,064.00
▼-1.01%
TSLA
$375.68
▲+1.37%
MSFT
$526.10
▲+1.66%
INTC
$116.93
▼-2.01%
SNDK
$1,718.50
▼-0.09%
META
$742.58
▲+1.99%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Morphosys Ag
(OP:
MPSYF
)
73.27
UNCHANGED
Last Price
Updated: 3:33 PM EDT, Jul 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphosys Ag
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
August 27, 2024
Via
ACCESSWIRE
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
April 24, 2024
Via
ACCESSWIRE
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
Via
ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
March 21, 2024
Via
ACCESSWIRE
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
March 07, 2024
Via
ACCESSWIRE
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
November 09, 2023
Via
ACCESSWIRE
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
March 09, 2023
Via
ACCESSWIRE
MorphoSys AG: Financial Calendar 2023
November 28, 2022
Via
ACCESSWIRE
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
Via
ACCESSWIRE
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
Via
ACCESSWIRE
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
Via
ACCESSWIRE
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
November 02, 2023
Via
ACCESSWIRE
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
October 25, 2023
Via
ACCESSWIRE
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
September 12, 2023
Via
ACCESSWIRE
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
March 02, 2023
Via
ACCESSWIRE
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
November 10, 2022
Via
ACCESSWIRE
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
October 21, 2022
Via
ACCESSWIRE
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
March 02, 2023
Via
ACCESSWIRE
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
January 09, 2023
Via
ACCESSWIRE
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
January 05, 2023
Via
ACCESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
November 03, 2022
Via
ACCESSWIRE
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
October 27, 2022
Via
ACCESSWIRE
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
October 27, 2022
Via
ACCESSWIRE
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Conference Call Alert
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022...
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
From
MorphoSys AG
Via
AccessWire
